BOSTON, May 14, 2024 (GLOBE NEWSWIRE) — MEACOR Inc. is pleased to announce the successful closing of its $15 million Series A funding round. This substantial investment supports MEACOR’s mission to offer a novel transcatheter approach for the treatment of mitral and tricuspid valve regurgitation.
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
